Press Releases

News Brief

Samsung Biologics joins strategic investment in and pursues a research collaboration with AimedBio to foster next-generation biotechnologies

Samsung Biologics joins strategic investment in and pursues a research collaboration with AimedBio to foster next-generation biotechnologies
 

Samsung Biologics has joined an equity investment in AimedBio, a Korean biotech company pioneering antibody-drug conjugate (ADC) technology. The investment was made through the Samsung Life Science Fund—a strategic investment fund set up by Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation.

 

Based on multi-omics and AI-driven big data analysis of patient samples, AimedBio specializes in the discovery and development of life-saving medicines for patients with severe neurological diseases, such as brain cancer, Alzheimer’s disease, and Parkinson’s disease. AimedBio has also developed a robust therapeutic pipeline, including a first-in-class ADC experimental drug targeting FGFR3 for brain and bladder cancers, which is expected to enter clinical trials in 2024. 

 

In addition to the investment, Samsung Biologics signed a research collaboration agreement to co-develop ADC toolbox technologies and a contract development agreement to support the development of AimedBio’s monoclonal antibody therapy for atopic dermatitis and dementia.

 

These agreements reflect Samsung Biologics’ commitment to exploring and developing innovative technologies for next-generation biomedicines. The Company plans to expand its business portfolio to include ADCs and is currently building its own separate ADC manufacturing facility with the goal to complete construction in 2024.

 

“We are pleased to support AimedBio for their pipeline of innovative candidates towards the clinic,” said John Rim, President and CEO of Samsung Biologics. “As part of our continued efforts in fostering next-generation technologies, we hope this investment paves the way for future collaborations on the development and manufacturing of new drugs.”

 Samsung Biologics joins strategic investment in and pursues a research collaboration with AimedBio to foster next-generation biotechnologies

 

Samsung Biologics has joined an equity investment in AimedBio, a Korean biotech company pioneering antibody-drug conjugate (ADC) technology. The investment was made through the Samsung Life Science Fund—a strategic investment fund set up by Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation.

 

Based on multi-omics and AI-driven big data analysis of patient samples, AimedBio specializes in the discovery and development of life-saving medicines for patients with severe neurological diseases, such as brain cancer, Alzheimer’s disease, and Parkinson’s disease. AimedBio has also developed a robust therapeutic pipeline, including a first-in-class ADC experimental drug targeting FGFR3 for brain and bladder cancers, which is expected to enter clinical trials in 2024. 

 

In addition to the investment, Samsung Biologics signed a research collaboration agreement to co-develop ADC toolbox technologies and a contract development agreement to support the development of AimedBio’s monoclonal antibody therapy for atopic dermatitis and dementia.

 

These agreements reflect Samsung Biologics’ commitment to exploring and developing innovative technologies for next-generation biomedicines. The Company plans to expand its business portfolio to include ADCs and is currently building its own separate ADC manufacturing facility with the goal to complete construction in 2024.

 

“We are pleased to support AimedBio for their pipeline of innovative candidates towards the clinic,” said John Rim, President and CEO of Samsung Biologics. “As part of our continued efforts in fostering next-generation technologies, we hope this investment paves the way for future collaborations on the development and manufacturing of new drugs.”

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION